Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
暂无分享,去创建一个
G. Tricot | P. Lin | Carla S. Wilson | R. Owens | Carla S Wilson | Guido Tricot | Pei Lin | Rebecca Owens
[1] R. Ohno,et al. Clinicopathological and prognostic characteristics of CD56‐negative multiple myeloma , 2002, British journal of haematology.
[2] S. Treon,et al. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. , 2000, Seminars in oncology.
[3] M. Dhodapkar,et al. Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions , 2001, Modern Pathology.
[4] Shaji K. Kumar,et al. Expression of CD52 on plasma cells in plasma cell proliferative disorders. , 2003, Blood.
[5] B. Barlogie. Plasma cell myeloma , 2001 .
[6] A. Órfão,et al. Expression of the CD117 antigen (C‐Kit) on normal and myelomatous plasma cells , 1996, British journal of haematology.
[7] S. Ely,et al. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. , 2002, The American journal of pathology.
[8] Ana Helena Santos,et al. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. , 2000, Blood cells, molecules & diseases.
[9] 原田 浩徳. Phenotypic difference of normal plasma cells from mature myeloma cells , 1993 .
[10] B. Barlogie,et al. Cytoplasmic immunoglobulin content in multiple myeloma. , 1985, The Journal of clinical investigation.
[11] C. D. Wu,et al. Differential diagnosis of malignant lymphomas and related disorders by specific pattern of expression of immunophenotypic markers revealed by multiparameter flow cytometry (Review). , 2000, International journal of oncology.
[12] B. Klein,et al. A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1 , 1996, British journal of haematology.
[13] T. Therneau,et al. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. , 1998, Leukemia & lymphoma.
[14] S. Barrans,et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression , 1999, British journal of haematology.
[15] A. Órfão,et al. High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma , 1999, British journal of haematology.
[16] T. Rasmussen,et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma , 2002, British journal of haematology.
[17] M. Jourdan,et al. The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells , 1998, British journal of haematology.
[18] A. Órfão,et al. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. , 2001, Cytometry.
[19] G. Morgan,et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.